LiverLearning®: 2021 Webinar: Biliary Atresia: Where We Are and Where Do We Go from Here?

Biliary atresia (BA) is a rapidly progressive inflammatory fibro-obliterative process affecting intra and extra hepatic bile ducts. BA is the most common indication for liver transplantation in children, however the etiopathogenesis is not completely understood. This one hour webinar will summarize genomics in BA, current diagnostic algorithms and novel prognosticators for BA, and long term outcomes of BA. Learners will gain understanding of current practices and future directions in etiopathogenesis and outcomes of BA.Kathleen M. Loomes Kathleen M.

Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis

Richard Taubert, Bastian Engel, Jana Diestelhorst, Katharina L. Hupa‐Breier, Patrick Behrendt, Niklas T. Baerlecken, Kurt‐Wolfram Sühs, Maciej K. Janik, Kalliopi Zachou, Marcial Sebode, Christoph Schramm, María‐Carlota Londoño, Sarah Habes, the UK‐AIH Consortium, Ye H. Oo, Claudine Lalanne, Simon Pape, Maren Schubert, Michael Hust, Stefan Dübel, Mario Thevis, Danny Jonigk, Julia Beimdiek, Falk F. R. Buettner, Joost P. H. Drenth, Luigi Muratori, David H. Adams, Jessica K. Dyson, Amédée Renand, Isabel Graupera, Ansgar W. Lohse, George N.

Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease

Ashwini Arvind, Jacqueline B. Henson, Stephanie A. Osganian, Cheryl Nath, Lara M. Steinhagen, Zoe N. Memel, Arley Donovan, Oluwafemi Balogun, Raymond T. Chung, Tracey G. Simon, Kathleen E. Corey – 1 September 2021 – Nonalcoholic fatty liver disease (NAFLD) is independently associated with obesity and cardiovascular disease (CVD). CVD is the primary cause of mortality in the predominantly obese population of adults with NAFLD.

Wilson’s Disease: An Analysis of Health Care Use and Cost Burden of Commercially Insured Adults in the United States

Vinod K. Rustgi, Kapil Gupta, Christopher Tait, Abhishek Bhurwal, Savan Kabaria, Carolyn Catalano, You Li, Carlos D. Minacapelli – 1 September 2021 – The economic and health care use burdens of Wilson’s disease (WD) are unknown. In this study, we aimed to quantify this health care resource use and economic burden. We performed a retrospective case‐control analysis of individuals in the Truven Health MarketScan Commercial Claims database (2007‐2017). Using propensity scores, 424 WD cases were matched 1:1 to chronic liver disease (CLD) controls without WD.

Predictors of Jaundice Resolution and Survival After Endoscopic Treatment of Primary Sclerosing Cholangitis

John E. Eaton, Abdul Haseeb, Christian Rupp, Leonardo H. Eusebi, Kim Munster, Robert Voitl, Douglas Thorburn, Cyriel Y. Ponsioen, Felicity T. Enders, Bret T. Petersen, Barham K. Abu Dayyeh, Todd H. Baron, Vinay Chandrasekhara, Christopher J. Gostout, Michael J. Levy, John Martin, Andrew C. Storm, Ross Dierkhising, Patrick S. Kamath, Gregory J. Gores, Mark Topazian – 31 August 2021 – The benefit of endoscopic retrograde cholangiopancreatography (ERCP) for the treatment of primary sclerosing cholangitis (PSC) remains controversial.

Subscribe to